Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. increased its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERVFree Report) by 89.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 12,094 shares of the company’s stock after acquiring an additional 5,723 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Verve Therapeutics were worth $59,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of VERV. Vanguard Group Inc. boosted its stake in Verve Therapeutics by 15.7% in the 1st quarter. Vanguard Group Inc. now owns 6,331,312 shares of the company’s stock worth $84,080,000 after buying an additional 859,382 shares during the last quarter. Nikko Asset Management Americas Inc. boosted its holdings in shares of Verve Therapeutics by 8.1% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 2,592,198 shares of the company’s stock valued at $34,347,000 after purchasing an additional 194,594 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Verve Therapeutics by 8.1% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,592,198 shares of the company’s stock valued at $34,424,000 after buying an additional 194,594 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Verve Therapeutics by 1.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 369,670 shares of the company’s stock valued at $5,153,000 after buying an additional 6,626 shares during the period. Finally, Rafferty Asset Management LLC increased its holdings in shares of Verve Therapeutics by 10.0% during the 4th quarter. Rafferty Asset Management LLC now owns 351,904 shares of the company’s stock worth $4,906,000 after buying an additional 32,104 shares during the last quarter. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Stock Down 0.6 %

NASDAQ VERV opened at $5.39 on Wednesday. Verve Therapeutics, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $20.12. The stock has a market cap of $452.57 million, a PE ratio of -1.88 and a beta of 1.83. The business has a 50 day moving average price of $6.01 and a two-hundred day moving average price of $7.20.

Verve Therapeutics (NASDAQ:VERVGet Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.09. The business had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $2.40 million. Verve Therapeutics had a negative return on equity of 35.20% and a negative net margin of 933.08%. The company’s revenue was up 219.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.87) earnings per share. Sell-side analysts anticipate that Verve Therapeutics, Inc. will post -2.65 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on VERV shares. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Verve Therapeutics in a research note on Monday, August 12th. Canaccord Genuity Group decreased their price objective on shares of Verve Therapeutics from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, Royal Bank of Canada cut their target price on shares of Verve Therapeutics from $25.00 to $20.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Verve Therapeutics currently has an average rating of “Buy” and an average target price of $26.00.

Check Out Our Latest Report on Verve Therapeutics

About Verve Therapeutics

(Free Report)

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

See Also

Want to see what other hedge funds are holding VERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verve Therapeutics, Inc. (NASDAQ:VERVFree Report).

Institutional Ownership by Quarter for Verve Therapeutics (NASDAQ:VERV)

Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.